KKR & Co (NYSE:KKR) will report on Q2 2022.
MyMD Pharmaceuticals And Charles River Present Data For Next Generation, Oral TNF-α Inhibitor MYMD-1 In Rheumatoid Arthritis
Preclinical results showed MYMD-1® significantly reduced histopathological changes and the severity of standard arthritis clinical trial measures compared to placebo; demonstrate future potential to disrupt the TNF-α inhibitor market
